BostonSight

BostonSight has pioneered the use of custom-designed scleral lenses and prosthetic devices for treating complex corneal diseases and severe dry eye since its founding in 1992. Its flagship treatments—PROSE® and the commercially available BostonSight SCLERAL®—are used worldwide. The organization operates an FDA-compliant lab in Massachusetts, conducts research on device innovation, provides education to practitioners globally, and partners with leading academic centers. Their Smart360 software enables highly customized lens fitting based on patient data. Clinical outcomes have shown significant improvements in vision quality and quality of life for patients with otherwise untreatable ocular conditions.